Ovenox 4000 Anti-Xa IU/0.4 ml (SC Injection)

0.4 ml pre-filled syringe: ৳ 461.38

Medicine Details

Category Details
Generic Enoxaparin sodium
Company Synovia pharma plc
Also available as
Ovenox 2000 anti xa injection Ovenox 6000 anti xa injection Ovenox 8000 anti xa injection

Indications

  • Treatment of deep vein thrombosis
  • Treatment of unstable angina and non-Q-wave myocardial infarction
  • Prevention of thrombus formation in extra-corporeal circulation during haemodialysis
  • Prophylaxis of venous thromboembolic disease in surgical patients
  • Prophylaxis of venous thromboembolic disease in medical patients

Composition

  • Enoxaparin Sodium BP 20 mg
  • Enoxaparin Sodium BP 40 mg
  • Enoxaparin Sodium BP 60 mg
  • Enoxaparin Sodium BP 80 mg

Pharmacology

  • Low molecular weight heparin
  • High anti-Xa activity
  • Low anti-IIa or antithrombin activity
  • Metabolized in the liver

Dosage

  • Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days
  • Subcutaneously 150 anti-Xa lU/kg once daily for 10 days
  • Subcutaneously 100 anti-Xa lU/kg twice daily for 2-8 days
  • Recommended dose of 100 anti-Xa lU/kg for haemodialysis
  • Subcutaneously 2000 anti-Xa IU (0.2 ml) once daily for 7-10 days
  • Subcutaneously 4000 anti-Xa IU (0.4 ml) once daily for 7-10 days

Administration

  • Instructions for self-injection
  • Selecting correct dose
  • Injecting into fatty tissue of the stomach
  • Disposal of used syringe into sharps container

Interaction

  • Discontinuation of agents affecting hemostasis prior to therapy
  • Careful monitoring for combination therapy

Contraindications

  • Hypersensitivity to Enoxaparin Sodium
  • Active major bleeding
  • High risk of uncontrolled hemorrhage

Side Effects

  • Haemorrhage
  • Thrombocytopenia
  • Elevations of serum aminotransferase
  • Pain and bluish marks at injection sites

Pregnancy & Lactation

  • Pregnancy category B
  • No evidence of crossing placental barrier
  • Decision making for use during pregnancy and lactation

Precautions & Warnings

  • Deep subcutaneous or intravascular administration
  • Caution in conditions with increased potential for bleeding
  • Measurement of platelet counts before and during treatment

Use in Special Populations

  • No dosage adjustment necessary in elderly patients
  • Careful observation for signs and symptoms of bleeding in renal impairment
  • Caution in hepatically impaired patients

Overdose Effects

  • Hemorrhagic complications
  • Neutralization with protamine sulfate

Therapeutic Class

  • Parenteral anti-coagulants

Storage Conditions

  • Cool and dry place
  • Protection from light and moisture
  • Do not store above 25°C
  • Keep out of the reach of children

Related Brands